Central India Chronicle

CRISPR Therapies Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

CRISPR Therapies Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

May 11
19:36 2023
CRISPR Therapies Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies,  Mechanism of Action, Route of Administration by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, CRISPR Therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The CRISPR Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

CRISPR Therapies Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR Therapies Market.

 

Some of the key takeaways from the CRISPR Therapies Pipeline Report:

  • Companies across the globe are diligently working toward developing novel CRISPR Therapies treatment therapies with a considerable amount of success over the years. 
  • CRISPR Therapies companies working in the treatment market are CRISPR therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, Caribou Biosciences, Inc., KSQ Therapeutics, Graphite Bio, Editas Medicine, Beam Therapeutics, Spotlight Therapeutics, and others, are developing therapies for the CRISPR Therapies treatment 
  • Emerging CRISPR Therapies therapies such as – CTX 130, NTLA-2002, LBP-EC01, CTX001, CB-010, KSQ-4279, GPH101, EDIT-101, BEAM-301, CRISPR gene editing therapeutics, and others are expected to have a significant impact on the CRISPR Therapies market in the coming years.   
  • In August 2022, Participants with severe sickle cell disease (SCD) or transfusion dependent -thalassemia (TDT) were enrolled in a single-dose, open-label research by CRISPR Therapeutics. CTX001 will be used in the study to assess the security and effectiveness of autologous CRISPR-Cas9 edited CD34+ human hematopoietic stem and progenitor cells (hHSPCs)
  • In May 2022, Paediatric TDT patients were enrolled in a single-dose, open-label research by CRISPR Therapeutics. Human hematopoietic stem and progenitor cells (hHSPCs) that have undergone autologous CRISPR-Cas9 modification and are CD34+ (CTX001) will be tested for both safety and effectiveness. With 12 people now enrolled, the experiment is expected to be finished by May 2026.

 

CRISPR Therapies Overview

Specialised DNA stretches are known as CRISPRs. The acronym “CRISPR” stands for “clusters of regularly interspaced short palindromic repeats.” Nucleotide repeats and spacers are two distinctive features of this specialised section of DNA. The DNA’s building units, nucleotides, are spread throughout a CRISPR region in repeated sequences.

 

Get a Free Sample PDF Report to know more about CRISPR Therapies Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight

 

Emerging CRISPR Therapies Drugs Under Different Phases of Clinical Development Include:

  • CTX 130: CRISPR therapeutics
  • NTLA-2002: Intellia Therapeutics, Inc.
  • LBP-EC01: Locus Biosciences
  • CTX001: CRISPR Therapeutics
  • CB-010: Caribou Biosciences, Inc.
  • KSQ-4279: KSQ Therapeutics
  • GPH101: Graphite Bio
  • EDIT-101: Editas Medicine
  • BEAM-301: Beam Therapeutics
  • CRISPR gene editing therapeutics: Spotlight Therapeutics

 

Route of Administration

CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

CRISPR Therapies Pipeline Therapeutics Assessment

  • CRISPR Therapies Assessment by Product Type
  • CRISPR Therapies By Stage and Product Type
  • CRISPR Therapies Assessment by Route of Administration
  • CRISPR Therapies By Stage and Route of Administration
  • CRISPR Therapies Assessment by Molecule Type
  • CRISPR Therapies by Stage and Molecule Type

 

DelveInsight’s CRISPR Therapies Report covers around 30+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further CRISPR Therapies product details are provided in the report. Download the CRISPR Therapies pipeline report to learn more about the emerging CRISPR Therapies therapies

 

Some of the key companies in the CRISPR Therapies Therapeutics Market include:

Key companies developing therapies for CRISPR Therapies are – Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Beam Therapeutics, Mammoth Biosciences, Caribou Biosciences, Synthego Corporation, CRISPR-Cas9 Therapeutics, Horizon Discovery Group, Precision Biosciences, Cellectis, ERS Genomics, Casebia Therapeutics, Poseida Therapeutics, Inscripta, Excision BioTherapeutics, GenScript Biotech Corporation, Sangamo Therapeutics, Mammoth Biosciences, Arbor Biotechnologies, and others.

 

CRISPR Therapies Pipeline Analysis:

The CRISPR Therapies pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of CRISPR Therapies with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRISPR Therapies Treatment.
  • CRISPR Therapies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • CRISPR Therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CRISPR Therapies market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about CRISPR Therapies drugs and therapies

 

CRISPR Therapies Pipeline Market Drivers

  • New drugs are discovered employing the novel ways to treat diseases, CRISPR/Cas9 provides extensive opportunities for programmable gene editing are some of the important factors that are fueling the CRISPR Therapies Market.

 

CRISPR Therapies Pipeline Market Barriers

  • However, unwanted immune responses, off-target effects, CRISPR has tangible progress for localized administration and other factors are creating obstacles in the CRISPR Therapies Market growth.

 

Scope of CRISPR Therapies Pipeline Drug Insight    

  • Coverage: Global
  • Key CRISPR Therapies Companies: CRISPR therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, Caribou Biosciences, Inc., KSQ Therapeutics, Graphite Bio, Editas Medicine, Beam Therapeutics, Spotlight Therapeutics, and others
  • Key CRISPR Therapies Therapies: CTX 130, NTLA-2002, LBP-EC01, CTX001, CB-010, KSQ-4279, GPH101, EDIT-101, BEAM-301, CRISPR gene editing therapeutics, and others
  • CRISPR Therapies Therapeutic Assessment: CRISPR Therapies current marketed and CRISPR Therapies emerging therapies
  • CRISPR Therapies Market Dynamics: CRISPR Therapies market drivers and CRISPR Therapies market barriers 

 

Request for Sample PDF Report for CRISPR Therapies Pipeline Assessment and clinical trials

 

Table of Contents

1

CRISPR Therapies Report Introduction

2

CRISPR Therapies Executive Summary

3

CRISPR Therapies Overview

4

CRISPR Therapies- Analytical Perspective In-depth Commercial Assessment

5

CRISPR Therapies Pipeline Therapeutics

6

CRISPR Therapies Late Stage Products (Phase II/III)

7

CRISPR Therapies Mid Stage Products (Phase II)

8

CRISPR Therapies Early Stage Products (Phase I)

9

CRISPR Therapies Preclinical Stage Products

10

CRISPR Therapies Therapeutics Assessment

11

CRISPR Therapies Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

CRISPR Therapies Key Companies

14

CRISPR Therapies Key Products

15

CRISPR Therapies Unmet Needs

16 

CRISPR Therapies Market Drivers and Barriers

17

CRISPR Therapies Future Perspectives and Conclusion

18

CRISPR Therapies Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services